MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. 

MDxHealth is listed on the Euronext under the ticker symbol MDXH.

MDxHealth has been listed on Euronext since June 2006. There is only one class of shares in the company (common shares) and all shares have the same rights and voting representation. There are no other financial instruments issued by the company other than stock options issued to employees, directors, and some consultants.

MDxHealth Corporate Presentation

MDxHealth 2018 H1 Corporate Presentation

MDxHealth 2018 Corporate Presentation

MDxHealth 2017 Investor Call Recording - Audio Only

MDxHealth 2017 FY Financial Results Presentation

MDxHealth 2017 H1 Results Call Transcript

MDxHealth 2017 H1 Results Presentation

MDxHealth Presentation at 2017 Canaccord Genuity Growth Conference

MDxHealth 2017 PDF Corporate Presentation

MDxHealth FY 2016 PDF Presentation

MDxHealth FY 2016 Audio

MDxHealth Webcasts & Multimedia

July 2016 Nieuwe test legt overdiagnostiek aan banden

May 2016 CEO & President Dr. Jan Groen's Interview from De Gids voor de Beste Belegger

March 22, 2016 MDxHealth featured in Initie De La Bourse-See page 5 (French)

March 22, 2016 MDxHealth featured in Inside Beleggen-See page 5 (Dutch)

January 26, 2016 CEO Jan Groen Ph.D. Bolero Interview

November 19, 2015, 4:00 PM EST: 9th Annual Canaccord Medical Technology & Diagnostics Forum

September 15, 2015, 3:10 PM CET: Building a Leader in Urological Diagnostics